From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Topics>
  3. Breast Cancer>
  4. Archives

Breast Cancer: Archives

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.

Items 1-25 of 407 are shown

Younger Breast Cancer Survivors Have Unique Concerns

A systematic review focuses on quality of life, emotional health, and menopause- and fertility-related issues in survivors age 50 or younger.

New Insights into the Biology of Metastasis

Cancer stem cells and endothelial signaling might point to novel therapies.

The 2011 San Antonio Breast Cancer Symposium

Highlights include adjuvant bisphosphonates, endocrine therapy, treatment of HER2-positive breast cancer, and genomic scores for predicting risk for recurrence of ductal carcinoma in situ.

Dual Antibodies Reap Benefits Against HER2-Positive Metastatic Breast Cancer

Adding pertuzumab to trastuzumab plus docetaxel prolonged progression-free survival without raising risk for cardiac events.

Adjuvant Radiation Therapy for Breast Cancer Affects Coronary Arteries

Stenosis occurred in certain regions of the arterial tree, but contemporary RT has evolved to minimize this risk.

Biopsy of Recurrent Breast Cancer Can Tell an Important Story

Marker discordance between primary and metastatic tumors affects management decisions and patients' outcomes.

Breast Cancer Prognosis and Management: Role of Gene Expression Profiling

Molecular signatures are increasingly important for guiding treatment recommendations.

Another Taxane Doublet for Metastatic Breast Cancer?

Adding gemcitabine to docetaxel did not improve outcomes significantly.

Will Axillary Radiotherapy Replace Axillary Dissection in Women with Positive Sentinel Nodes?

For management of early breast cancer, sufficiency of local therapy must be balanced against risk for overtreatment.

Detection Rates Are Similar for Digital and Film Mammography

Digital mammography had better sensitivity when breast tissue was dense.

When BRCA Mutations Run in the Family, Should Noncarriers Worry?

Population-based study shows that noncarriers are not at excess risk for breast cancer attributable to familial mutations.

Adjuvant Letrozole Continues to Best Tamoxifen for Early Breast Cancer

Letrozole monotherapy was better than tamoxifen monotherapy; sequential letrozole and tamoxifen were not better than letrozole alone.

Improving Prediction of Breast Cancer Recurrence

Prediction models that included traditional pathologic and clinical information alongside the results of a genomic assay performed better than models that included only the results of the assay.

Benefits of Radiotherapy After Breast-Conserving Surgery

Long-term meta-analysis shows lower risks for recurrence and breast cancer death.

BRCA1 Mutations and Triple-Negative Breast Cancer

In <$EMPH_O>BRCA1<$EMPH_C> carriers and noncarriers, TNBC had distinct clinical characteristics.

Odds of False-Positive Mammograms During 10 Years of Screenings

The cumulative probabilities of false-positive mammography results were 60% and 40% for annual and biennial screening, respectively.

Revisiting the Bottle: Alcohol and Breast Cancer Risk

Low levels of alcohol consumption are associated with moderately elevated risk, but benefits of alcohol should also be considered.

Annual or Biennial Screening Mammography: Which Is Better?

Large U.S. study suggests annual screens increase likelihood of unneeded recalls and biopsies without raising risk for late-stage cancer diagnosis; but debate continues.

Revisiting the Sequence of Adjuvant Chemotherapy and Endocrine Therapy in Breast Cancer

Long-term results suggest that concurrent chemo-endocrine therapy should be reconsidered as an option.

Relieving Hot Flashes in Breast Cancer Survivors

Venlafaxine and clonidine were statistically superior to placebo.

A Better Test for HER2 Status? Not Yet.

The false-negative rate of Onco<$EMPH_O>type<$EMPH_C> DX qRT-PCR was >50%.

Avoiding Adjuvant Anthracylines for HER2-Positive Breast Cancer

Docetaxel and carboplatin plus trastuzumab might be a particularly appropriate choice for women with cardiac risk factors.

Another Helping of Flaxseed for Breast Cancer?

High levels of serum enterolactone were associated with lower risk for death during follow-up in women with hormone receptor–negative tumors.

Markers of Risk for Bone Metastases in Breast Cancer

Higher serum beta C-terminal telopeptide levels predicted shorter relapse-free survival in women with bone-only metastases.

Trastuzumab Keeps On Giving

Beneficial effects are long-lasting in patients with HER2-positive, early-stage breast cancer.

Items 1-25 of 407 are shown

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?





Copyright © 2012. Massachusetts Medical Society. All rights reserved.